Cargando…
Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
A series of three dose escalating studies were conducted to investigate the ability of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a single...
Autores principales: | O'Donnell, A, Judson, I, Dowsett, M, Raynaud, F, Dearnaley, D, Mason, M, Harland, S, Robbins, A, Halbert, G, Nutley, B, Jarman, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409523/ https://www.ncbi.nlm.nih.gov/pubmed/15150570 http://dx.doi.org/10.1038/sj.bjc.6601879 |
Ejemplares similares
-
New insights on hyperglycemia in 17-hydroxylase/17,20-lyase deficiency
por: Xu, Lingling, et al.
Publicado: (2022) -
17α-hydroxylase/17,20-lyase deficiency in congenital adrenal hyperplasia: A case report
por: Xu, Simiao, et al.
Publicado: (2017) -
17α-Hydroxylase/17,20-Lyase Deficiency in 46,XY: Our Experience and Review of Literature
por: Maheshwari, Madhur, et al.
Publicado: (2022) -
Dexamethasone application for in vitro fertilisation in non-classic 17-hydroxylase/17,20-lyase-deficient women
por: Yang, Xiu-Li, et al.
Publicado: (2022) -
Two cases of 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 mutation
por: Lee, Hae In, et al.
Publicado: (2021)